Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

Articles

Future of Treating mRCC

July 23rd 2020

Treating Patients With mRCC Beyond Second-Line

July 23rd 2020

Strategies for Switching From Frontline Therapy to Second-Line Therapy in mRCC

July 23rd 2020

Clinical Trials Shaping Treatment in Relapsed/Refractory mRCC

July 23rd 2020

Choosing Second-Line Therapy in Treatment of mRCC

July 23rd 2020

Tailored Therapy Approaches for Upfront mRCC Treatment

July 23rd 2020

Treating Side Effects of Therapy for mRCC with Steroids

July 23rd 2020

Evaluating Safety Profiles of Upfront Regimens for mRCC

July 23rd 2020

Choosing Upfront Therapy for mRCC

July 23rd 2020

CheckMate 9ER: Phase 3 Trial of Frontline Nivolumab + Cabozantinib

July 23rd 2020

Evaluating Long-Term Follow-Up Data for Treatment of mRCC

July 23rd 2020

Patient Factor Consideration for Treatment of mRCC

July 23rd 2020

Applying Clinical Trial Data for Treatment of mRCC

July 23rd 2020

Clinical Trials Defining the NCCN Guidelines for Frontline Treatment of mRCC

July 23rd 2020

Evaluation of Risk for Frontline Advanced/Metastatic Clear Cell RCC

July 23rd 2020

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

June 19th 2020

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate Cancer

February 19th 2020

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.

Dr. Pal on Cohort Findings of COSMIC-021 Trial in mCRPC

February 14th 2020

Sumanta K. Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, medical oncologist, City of Hope, discusses the phase Ib results of cohort 6 from the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer.

Dr. Pal Compares CheckMate-214 and CABOSUN Trials in RCC

September 13th 2017

Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses both the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).